Nivolumab, Ipilimumab, Pumitamig, Cabozantinib
Advanced Renal Cell Carcinoma (Rcc)
Not Yet Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)